CN112245436A - Application of 18 beta-glycyrrhetinic acid in preparation of product for enhancing anti-fatigue capability of organism - Google Patents
Application of 18 beta-glycyrrhetinic acid in preparation of product for enhancing anti-fatigue capability of organism Download PDFInfo
- Publication number
- CN112245436A CN112245436A CN202011335690.8A CN202011335690A CN112245436A CN 112245436 A CN112245436 A CN 112245436A CN 202011335690 A CN202011335690 A CN 202011335690A CN 112245436 A CN112245436 A CN 112245436A
- Authority
- CN
- China
- Prior art keywords
- fatigue
- exercise
- glycyrrhetinic acid
- beta
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 title claims abstract description 44
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 34
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 235000013402 health food Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000020195 rice milk Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 235000012041 food component Nutrition 0.000 abstract description 9
- 230000037080 exercise endurance Effects 0.000 abstract description 7
- 239000005417 food ingredient Substances 0.000 abstract description 6
- 230000033001 locomotion Effects 0.000 description 14
- 230000009469 supplementation Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000284 resting effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 102000004420 Creatine Kinase Human genes 0.000 description 8
- 108010042126 Creatine kinase Proteins 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000021283 resveratrol Nutrition 0.000 description 4
- 229940016667 resveratrol Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 239000005428 food component Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000013227 male C57BL/6J mice Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000003334 potential effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the field of health-care food, and particularly relates to application of 18 beta-glycyrrhetinic acid in preparation of a product for enhancing the anti-fatigue capability of an organism. The 18 beta-glycyrrhetinic acid has the effects of remarkably enhancing exercise endurance and delaying the occurrence of exercise-induced fatigue. The anti-fatigue food ingredients have the effect after being taken for a short time, and can enhance the exercise endurance of mice, prolong the exercise time and increase the exercise distance after being taken 2.5 hours before the exhaustion exercise. The invention provides a new component for developing anti-fatigue health-care food and has important application value.
Description
Technical Field
The invention belongs to the field of health-care food, and particularly relates to application of 18 beta-glycyrrhetinic acid in preparation of a product for enhancing the anti-fatigue capability of an organism.
Background
Fatigue is a phenomenon that is commonly found in the body, mediated by a complex series of physiological and biochemical processes. Fatigue is defined as the weakening of the force that a muscle can produce such that it cannot maintain a predetermined strength of movement, i.e. exercise fatigue. The generation of sports fatigue is often accompanied by changes in energy substances, metabolites, hormone levels, cellular metabolism regulating enzymes, antioxidant system enzymes and the like, and the essential reason of the generation is that the body feels uncomfortable due to the imbalance of homeostasis. The persistent fatigue or the severe fatigue not only affects the normal life of people, but also causes endocrine disturbance, immunity reduction and even organic diseases, thus threatening the health. The sports fatigue is caused by the crowds of over-trained athletes, fire-fighting officers and soldiers who continuously work at high intensity, medical staff, scientific research staff, labor people and the like. In addition, the general population may also often feel tired. Therefore, the development of anti-fatigue products suitable for the vast population has important and profound significance.
The functional food for resisting sports fatigue on the market contains various ingredients, and the ingredients are mainly divided into two main categories. One is basic substance required by body movement, such as saccharide, amino acid, inorganic salt, etc.; one is a functional factor based on its molecular regulation mechanism, which has the functions of increasing energy utilization rate, eliminating harmful metabolites (such as ROS), relieving body fatigue, etc., such as carnosine, carnitine, caffeine, ginsenoside, etc. Wherein the anti-fatigue action mechanism of part of substances relates to a nerve regulation mechanism and is suspected to be excitant; the anti-fatigue efficacy of some substances remains to be further verified; and part of the substances are expensive and are not suitable for consumption of the masses. Furthermore, most of the anti-fatigue substances found require long-term supplementation for at least 1 month to exert their effective effect.
Disclosure of Invention
One of the purposes of the invention is to provide a new application of 18 beta-glycyrrhetinic acid in the field of health-care food.
The invention provides a new application of 18 beta-glycyrrhetinic acid in the field of health food, which comprises the following steps: application of 18 beta-glycyrrhetinic acid as an anti-fatigue component in preparing a product for enhancing the anti-fatigue capability of an organism.
The product can be medicine, food, health food, etc.
The anti-fatigue capability may specifically be an anti-exercise fatigue capability.
When the 18 beta-glycyrrhetinic acid is used as an anti-fatigue component, the 18 beta-glycyrrhetinic acid is taken 2.5 hours before the start of exhaustion exercise and is taken once a day.
When the 18 beta-glycyrrhetinic acid is used as an anti-fatigue component, the anti-fatigue basic formula can be added to prepare powder, tablets, capsules and the like, and the anti-fatigue basic formula can also be added to food, such as biscuits, rice milk, milk powder, sesame paste and the like.
Another object of the present invention is to provide a health food capable of enhancing the anti-fatigue ability of the body.
The health food capable of enhancing the anti-fatigue capability of the organism provided by the invention takes 18 beta-glycyrrhetinic acid as an effective component.
The fatigue may specifically be sports fatigue.
The health food containing 18 beta-glycyrrhetinic acid as effective component and capable of enhancing body fatigue resistance is administered 2.5h before the start of exhaustion exercise, and is administered once per day.
The invention also provides a method for enhancing the anti-fatigue capability of the organism.
The method comprises the following steps: the preparation is administered once a day, and 18 beta-glycyrrhetinic acid or health food containing 18 beta-glycyrrhetinic acid as effective component and capable of enhancing fatigue resistance is administered 2.5h before the start of exhaustion exercise.
The liquorice is a common traditional Chinese medicine, and the 2015 edition of Chinese pharmacopoeia shows that the part of the liquorice used as the medicine is dry roots and rhizomes. Glycyrrhizic acid and glycyrrhetinic acid, which are the main bioactive components of the root, are considered to have a liver-protecting effect. After oral administration, glycyrrhizic acid is totally decomposed into 18 β -glycyrrhetinic acid in the small intestine by intestinal bacteria.
According to the pharmacopoeia, about 400mg of 18 beta-glycyrrhetinic acid is safe to be taken orally every day. The dosage of the product is safe according to the conversion formula, namely the daily oral dosage of a human body is the mouse dosage (mg/kg)/9.1 x 60.
Research shows that glycyrrhetinic acid has the effects of resisting oxidation, resisting inflammation, regulating glycolipid metabolism, protecting liver and the like. The research shows that the 18 beta-glycyrrhetinic acid has the function of resisting fatigue.
Experiments prove that the anti-sports fatigue food component can have the potential effects of prolonging endurance exercise and accelerating the exercise endurance of mice in a high-strength accelerated exercise fatigue model after being supplemented for 3 days continuously, the exercise time is prolonged by 7 percent (P is 0.007), the exercise distance is increased by 29 percent (P is 0.023), and speed setting and experimental results are shown in figures 1-3.
Experiments prove that the anti-sports fatigue food ingredients can effectively prolong the sports endurance of a mouse in a high-strength accelerated sports fatigue model after being supplemented for 3 days continuously, the percentage of the lengthening of the sports time is 26 percent (P is 0.034), the percentage of the increasing of the sports distance is 37 percent (P is 0.034), and the speed setting and the experimental results are shown in figures 4-6.
Experiments prove that the anti-sports fatigue food ingredient can effectively protect muscle damage caused by high-intensity sports after being supplemented for 3 days continuously, the creatine kinase reduction percentage is 38% (P is 0.015), and the creatine kinase basically falls back to the resting level, and the experimental results are shown in figure 7.
The food ingredients are scientifically and reasonably screened out the food-borne functional ingredients with the anti-fatigue effect according to the existing fatigue generation mechanism, such as the energy exhaustion theory, the metabolite accumulation theory, the internal environment homeostasis disorder theory of the organism, the oxygen free radical theory, the central fatigue and the like. It has the characteristics of naturalness, safety, high efficiency, no toxic or side effect, clear action way and the like. The product has effect in enhancing anti-fatigue ability after short-term administration, and can be administered 2.5 hr before the start of exhaustion exercise to enhance exercise endurance of mouse, prolong exercise time, and increase exercise distance.
The invention aims to provide a food component which has wide raw material source, high price, short supplement time and excellent anti-fatigue effect, and provides a new choice for the research of anti-fatigue formula products.
Drawings
Fig. 1 is a graph showing the speed and time settings of the endurance exercise + high-intensity accelerated exercise fatigue model in example 1 of the present invention.
FIG. 2 shows the effect of supplementing 18 β -glycyrrhetinic acid for 3 days on the motility time of mice in a resistance exercise + high-intensity accelerated exercise fatigue model.
FIG. 3 shows the effect of supplementing 18 β -glycyrrhetinic acid for 3 days on the distance to exercise exhaustion in mice in a resistance exercise + high-intensity accelerated exercise fatigue model.
Fig. 4 is a graph of the speed and time settings of the high intensity accelerated motion fatigue model in example 2 of the present invention.
FIG. 5 shows the effect of 3 days supplementation with 18 β -glycyrrhetinic acid on the time to exhaustion of locomotion in mice in a high-intensity accelerated exercise fatigue model.
FIG. 6 shows the effect of 3 days supplementation with 18 β -glycyrrhetinic acid on the time to exhaustion of locomotion in mice in a high-intensity accelerated exercise fatigue model.
FIG. 7 shows the effect of supplementation with 18 β -glycyrrhetinic acid for 3 days on creatine kinase in mouse serum for the same time period of exercise in a high intensity accelerated exercise fatigue model.
Detailed Description
The present invention will be described below with reference to specific examples, but the present invention is not limited thereto.
The experimental methods used in the following examples are all conventional methods unless otherwise specified; reagents, biomaterials, etc. used in the following examples are commercially available unless otherwise specified.
Example 1
The 18 beta-glycyrrhetinic acid can relieve the sports fatigue of a mouse in a resistance sports plus high-strength accelerated sports fatigue model.
The test method comprises the following steps: male C57 BL/6J mice, 36, 6-8 weeks old, all mice were randomly assigned to the resting group (12), model group (12), formula group (12). By adopting a stomach filling method, a resting group and a model group are filled with 0.1 percent of sodium carboxymethylcellulose every day, a formula group is filled with 25mg/kg bw of 18 beta-glycyrrhetinic acid every day, and a solvent is 0.1 percent of sodium carboxymethylcellulose. 8 in the morning: gavage is performed 30 times for 1 time. The supplementation was continued for 3 days, and 2.5 hours after the last supplementation, the motility exhaustion time of the mice was measured while the movement distance was calculated.
And (3) motion model: the experimental animal runs the platform. The gradient is 0 degree, the initial speed is 10m/min, 2m/min is added every 15min until 14m/min, the speed is accelerated to 20m/min after 15min, the speed is increased to 22m/min after 5min, 1m/min is added to 24m/min every 5min, and the running is continued until the vigor is exhausted. The movement speed and time settings are shown in figure 1.
The force criteria were set such that the mouse stayed on the electrodes for more than 1 minute and was still unable to run forward with a brush gently stimulating its tail or legs.
The experimental results (fig. 2 and 3) show that the anti-exercise fatigue food component is continuously supplemented for 3 days, has the potential effect of prolonging the exercise endurance and the exercise endurance of the mice in the high-intensity accelerated exercise fatigue model, the exercise time is prolonged by 7 percent (P is 0.007), and the exercise distance is increased by 29 percent (P is 0.023).
Example 2
The 18 beta-glycyrrhetinic acid can relieve the sports fatigue of the mouse in a high-strength accelerated sports fatigue model.
The test method comprises the following steps: male C57 BL/6J mice, 36, 6-8 weeks old, all mice were randomly assigned to the resting group (12), model group (12), administration group (12). By adopting a stomach filling method, a resting group and a model group are filled with 0.1 percent of sodium carboxymethylcellulose every day, an administration group is filled with 25mg/kg bw of 18 beta-glycyrrhetinic acid every day, and the solvent is 0.1 percent of sodium carboxymethylcellulose. 8 in the morning: gavage is performed 30 times for 1 time. The supplementation was continued for 3 days, and 2.5 hours after the last supplementation, the motility exhaustion time of the mice was measured while the movement distance was calculated.
And (3) motion model: the experimental animal runs the platform. The slope is 0 degree, the initial speed is 5m/min, 5m/min is added every 5min, and after the speed is increased to 25m/min, the running is continued until the exhaustion. The movement speed and time settings are shown in figure 4.
The force criteria were set such that the mouse stayed on the electrodes for more than 10 seconds and was still unable to run forward with a brush gently stimulating its tail or legs.
The results of the experiment (fig. 5 and 6) show that the anti-exercise fatigue food ingredient is continuously supplemented for 3 days, and has the potential effect of prolonging the exercise endurance of the mice in the high-intensity accelerated exercise fatigue model, the exercise time is prolonged by 26 percent (P ═ 0.034), and the exercise distance is increased by 37 percent (P ═ 0.034).
The results of comparative example 1 and example 2 show that 18 β -glycyrrhetinic acid has a stronger anti-fatigue effect in the high-intensity accelerated exercise fatigue model than in the endurance exercise + high-intensity accelerated exercise fatigue model.
Example 3
Alleviation of muscle damage in mice in a high-intensity accelerated exercise fatigue model by 18 β -glycyrrhetinic acid.
The test method comprises the following steps: male C57 BL/6J mice, 36, 6-8 weeks old, all mice were randomly assigned to the resting group (12), model group (12), administration group (12). By adopting a stomach filling method, a resting group and a model group are filled with 0.1 percent of sodium carboxymethylcellulose every day, an administration group is filled with 25mg/kg bw of 18 beta-glycyrrhetinic acid every day, and the solvent is 0.1 percent of sodium carboxymethylcellulose. 8 in the morning: gavage is performed 30 times for 1 time. Continuously supplementing for 3 days, uniformly running for 20 minutes 2.5 hours after the last supplementation, taking blood, and measuring the content of creatine kinase in the blood serum of the mice.
And (3) motion model: the experimental animal runs the platform. The slope is 0 degree, the initial speed is 5m/min, 5m/min is added every 5min, and after the speed is increased to 25m/min, the running is continued until the exhaustion. The movement speed and time settings are shown in figure 4.
The force criteria were set such that the mouse stayed on the electrodes for more than 10 seconds and was still unable to run forward with a brush gently stimulating its tail or legs.
The experimental result (figure 7) shows that the continuous supplementation of the anti-sports fatigue food ingredient for 3 days can obviously reduce the increased serum creatine kinase content of the mice in a certain time of high-intensity accelerated exercise process, the reduction percentage is 38 percent (P ═ 0.015), and the creatine kinase basically falls back to the resting level, which indicates that the 18 beta-glycyrrhetinic acid has the function of delaying sports fatigue.
Comparative example 1
The existing literature indicates that resveratrol has the function of relieving the sports injury of mice in a high-strength accelerated sports fatigue model, but the relieving degree is not as good as that of 18 beta-glycyrrhetinic acid.
The test method comprises the following steps: male Wistar rats, 8 weeks old, were divided into resting group, model group, administration group. By adopting a gastric lavage method, the administration group is gavaged with 10mg/ml of resveratrol every day, and the solvent is a neutral aqueous solution. The stomach was perfused continuously for 5 weeks and run out experiments were performed.
And (3) motion model: the experimental animal runs the platform. The slope is 10 degrees, the speed is 25m/min, and the running is performed till exhaustion.
The force criteria were set such that the mouse stayed on the electrodes for more than 10 seconds and was still unable to run forward with a brush gently stimulating its tail or legs.
The experimental result shows that the continuous supplementation of resveratrol for 5 weeks can obviously reduce the creatine kinase level of mice after exercise, but cannot recover to the creatine kinase level of mice in a resting state, and the effect of veratryl alcohol on relieving injury caused by high-intensity exercise is not as good as that of 18 beta-glycyrrhetinic acid.
Reference documents:
Vafaee R,Soori H,Hedayati M,Ainy E,Hatamabadi H.Effects of resveratrol supplementation in male Wistar rats undergoing an endurance exercise and acute exercise training.Hum Antibodies.2019;27(4):257-264.doi:10.3233/HAB-190380.PMID:31127758.
Claims (9)
1.18 beta-glycyrrhetinic acid is used as an anti-fatigue component in the preparation of products for enhancing the anti-fatigue capability of organisms.
2. Use according to claim 1, characterized in that: the anti-fatigue capability is the capability of resisting sports fatigue.
3. Use according to claim 1 or 2, characterized in that: the product is a medicine, a food or a health food.
4. Use according to any one of claims 1-3, characterized in that: when the 18 beta-glycyrrhetinic acid is used as an anti-fatigue component, the 18 beta-glycyrrhetinic acid is taken 2.5 hours before the start of exhaustion exercise and is taken once a day.
5. Use according to any one of claims 1 to 4, characterized in that: when the 18 beta-glycyrrhetinic acid is used as an anti-fatigue component, the anti-fatigue basic formula can be added to prepare powder, tablets and capsules, and the anti-fatigue basic formula can also be added to food, wherein the food can be biscuit, rice milk, milk powder and sesame paste.
6. A health food for enhancing anti-fatigue ability of organism contains 18 beta-glycyrrhetinic acid as effective component.
7. The health food according to claim 6, wherein: the fatigue is sports fatigue.
8. The health food according to claim 6 or 7, wherein: the health food containing 18 beta-glycyrrhetinic acid as effective component and capable of enhancing body fatigue resistance is taken 2.5h before the start of exhaustion exercise, and is taken once a day.
9. A method for enhancing the anti-fatigue capability of a body comprises the following steps: administering 18 β -glycyrrhetinic acid or the health food according to any one of claims 6 to 8 once a day 2.5h before the start of exhaustion exercise of the body.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011335690.8A CN112245436B (en) | 2020-11-25 | 2020-11-25 | Application of 18 beta-glycyrrhetinic acid in preparation of product for enhancing anti-fatigue capability of organism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011335690.8A CN112245436B (en) | 2020-11-25 | 2020-11-25 | Application of 18 beta-glycyrrhetinic acid in preparation of product for enhancing anti-fatigue capability of organism |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112245436A true CN112245436A (en) | 2021-01-22 |
CN112245436B CN112245436B (en) | 2021-08-31 |
Family
ID=74225588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011335690.8A Active CN112245436B (en) | 2020-11-25 | 2020-11-25 | Application of 18 beta-glycyrrhetinic acid in preparation of product for enhancing anti-fatigue capability of organism |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112245436B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1415253A (en) * | 2002-09-24 | 2003-05-07 | 蒋兴民 | Beverage for regulating spirit |
CN101366698A (en) * | 2008-09-28 | 2009-02-18 | 中国药科大学 | Biogastrone acid prosome liposome with long circulation function and preparation method thereof |
EP2474314A1 (en) * | 2009-09-01 | 2012-07-11 | Uni-president Biotech Co., Ltd. | Antiphlogistic, antioncotic and analgesic chinese herbal composition preparative method and usage thereof |
CN104997787A (en) * | 2015-07-01 | 2015-10-28 | 中国人民解放军第二军医大学 | Application of glycyrrhetinic acid in preparation of anti-radiation product |
CN107997166A (en) * | 2016-11-01 | 2018-05-08 | 北京振东光明药物研究院有限公司 | A kind of health products and preparation method for improving sleep, relieving fatigue strengthen immunity |
CN110772494A (en) * | 2019-11-14 | 2020-02-11 | 西安交通大学医学院第二附属医院 | Fumailing capsule for preventing and treating bradyarrhythmia and preparation method thereof |
CN111961113A (en) * | 2020-05-26 | 2020-11-20 | 南京植创生物技术研究院有限公司 | Glycyrrhetinic acid and glycylglycine dipeptide compound and preparation method thereof |
-
2020
- 2020-11-25 CN CN202011335690.8A patent/CN112245436B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1415253A (en) * | 2002-09-24 | 2003-05-07 | 蒋兴民 | Beverage for regulating spirit |
CN101366698A (en) * | 2008-09-28 | 2009-02-18 | 中国药科大学 | Biogastrone acid prosome liposome with long circulation function and preparation method thereof |
EP2474314A1 (en) * | 2009-09-01 | 2012-07-11 | Uni-president Biotech Co., Ltd. | Antiphlogistic, antioncotic and analgesic chinese herbal composition preparative method and usage thereof |
CN104997787A (en) * | 2015-07-01 | 2015-10-28 | 中国人民解放军第二军医大学 | Application of glycyrrhetinic acid in preparation of anti-radiation product |
CN107997166A (en) * | 2016-11-01 | 2018-05-08 | 北京振东光明药物研究院有限公司 | A kind of health products and preparation method for improving sleep, relieving fatigue strengthen immunity |
CN110772494A (en) * | 2019-11-14 | 2020-02-11 | 西安交通大学医学院第二附属医院 | Fumailing capsule for preventing and treating bradyarrhythmia and preparation method thereof |
CN111961113A (en) * | 2020-05-26 | 2020-11-20 | 南京植创生物技术研究院有限公司 | Glycyrrhetinic acid and glycylglycine dipeptide compound and preparation method thereof |
Non-Patent Citations (5)
Title |
---|
CIRILLO ET AL.: "Keratinocytes Synthesize and Activate Cortisol", 《JOURNAL OF CELLULAR BIOCHEMISTRY》 * |
FREY ET AL.: "Pharmacology of 11β-hydroxysteroid dehydrogenase", 《STEROIDS》 * |
丁言镁 主编: "《当代科技与体育》", 31 August 2003, 中国科学文化出版社 * |
尚如霞 等: "四君子汤血清药效成分的HPLC-MS分析", 《江苏大学学报(医学版)》 * |
金敏 等: "甘草次酸药理作用的研究进展", 《医学综述》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112245436B (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cruz-Jentoft et al. | Nutritional strategies for maintaining muscle mass and strength from middle age to later life: A narrative review | |
Shimomura et al. | Branched-chain amino acid supplementation before squat exercise and delayed-onset muscle soreness | |
CA2563952C (en) | Uses of the pregnane glycosides in the treatment/management of obesity, obesity-related and other disorders | |
KR20090036579A (en) | Novel agents for the treatment of disorders connected to impaired neurotransmission | |
EP1997496B1 (en) | Composition containing riboflavin and sesamin-class compounds | |
WO2006021930A2 (en) | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp | |
US20140105878A1 (en) | Compositions and methods for prevention and treatment of migraines | |
WO2015015149A1 (en) | Dietary supplement | |
CN112245436B (en) | Application of 18 beta-glycyrrhetinic acid in preparation of product for enhancing anti-fatigue capability of organism | |
WO2004112511A2 (en) | Supplement for restoring growth hormone levels | |
WO2016062125A1 (en) | Use of reduced coenzyme ii | |
RU2376888C2 (en) | Dietary supplement | |
CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
WO2017186954A1 (en) | Method for the improvement of speed and endurance capacity | |
Serafini et al. | Nutritional approach to sarcopenia | |
PT2216039E (en) | Pharmaceutical compositions for treating anxiety | |
JPH0276813A (en) | Remedy for neurodegenerative disorder | |
RU2436415C2 (en) | Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome | |
RU2819538C1 (en) | Formulation of specialized sports nutrition for recovery, including prevention of arthritis and other joint diseases, and inclusion in the anti-age therapy program | |
US20240115590A1 (en) | Compositions and therapeutic methods for treating chronic sequalae following viral infections | |
JP2005126379A (en) | New synergetic composition of vitamins, minerals and trace element for stimulating elimination of intracellular lipid deposit | |
US20200246414A1 (en) | Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system | |
US20050143343A1 (en) | Nutritional supplement for enhancing the production and effect of natural human growth hormone | |
JP2012180331A (en) | Oral ingestion medicine for inducement of early recovery of muscle damage | |
CN116999422A (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyric acid (HMB) for joint stability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240104 Address after: 726207 North side of National Highway 312, Taoyuan Community, Shangzhen, Danfeng County, Shangluo City, Shaanxi Province Patentee after: Shaanxi Xinyudan Chinese Herbal Medicine Biotechnology Co.,Ltd. Address before: 100193 No. 2 Old Summer Palace West Road, Beijing, Haidian District Patentee before: CHINA AGRICULTURAL University |
|
TR01 | Transfer of patent right |